Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw

Research analysts at Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report issued on Thursday. The firm set a “buy” rating and a $20.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s target price suggests a potential upside of 64.34% from the company’s previous close.

A number of other equities analysts have also issued reports on ENTA. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Trading Up 0.7%

ENTA stock opened at $12.17 on Thursday. The company has a market capitalization of $353.17 million, a P/E ratio of -3.80 and a beta of 0.96. The business has a 50 day simple moving average of $13.45 and a 200-day simple moving average of $12.59. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. Research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Meeder Asset Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $32,000. Seven Fleet Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $36,000. Strs Ohio acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 333.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after buying an additional 2,758 shares in the last quarter. Finally, Quarry LP purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $81,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.